Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome
Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Based on NCEP-ATP III Criteria With Modification on Obesity Classification (Waist Circumference Measurement) for Asian Population
Sponsor: PT. Sahabat Lingkungan Hidup
A PHASE2 clinical study on Cardiometabolic Syndrome, this trial is ongoing. The trial is conducted by PT. Sahabat Lingkungan Hidup and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Enrolling By Invitation → Unknown Status
-
Nov 2021 — Nov 2023 [monthly]
Enrolling By Invitation PHASE2
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PT. Sahabat Lingkungan Hidup
- University of Brawijaya
For direct contact, visit the study record on ClinicalTrials.gov .